Daily Stock List
HealthWarehouse.com, Inc. (HEWA)
SeeThruEquityResearch, TopPennyStockMovers, DreamTeamNetwork, Stock News Now, Marketbeat, SmallCapVoice, and FeedBlitz reported earlier on HealthWarehouse.com, Inc. (HEWA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
HealthWarehouse.com, Inc. is a VIPPS-accredited online and mail-order pharmacy licensed in all 50 states. The Company is centering on the developing out of the pocket prescription market. HealthWarehouse.com is America’s only Verified Internet Pharmacy Practice Sites (VIPPs) and Vet-VIPPs accredited online and mail-order pharmacy licensed and/or authorized in all 50 states. VIPPS accreditation helps consumers to distinguish between legitimate and illegitimate pharmacies. HealthWarehouse.com is based in Florence, Kentucky.
HealthWarehouse.com has become the largest VIPPS accredited online pharmacy in the U.S. The Company’s mission is to provide affordable healthcare to every American through concentrating on technology that is transforming prescription delivery. HealthWarehouse.com only sells drugs that are Food and Drug Administration (FDA)-approved and legal for sale in the U.S.
The Company’s operations focus on a state-of-the-art pharmacy that can handle greater than 5,000 prescriptions daily. Currently, HealthWarehouse.com serves more than 450,000 unique customers. All of its products ship from its 28,000-square foot warehouse in Florence, Kentucky. The Company’s centralized location enables its products to reach 80 percent of the U.S. population within 2 to 3 days.
HealthWarehouse.com has met standards required by the Better Business Bureau (BBB) for accreditation with the organization. The BBB seal signifies to consumers’ merchants that value honesty and integrity. BBB Accreditation means HealthWarehouse.com adheres to very high ethical standards.
HealthWarehouse.com employs a team of highly educated, well trained pharmacists (RPh and/or PharmD) with over 90 years of clinical experience. All of the Company’s pharmacy technicians (CPhT) are Nationally Licensed Pharmacy Technicians through the Pharmacy Technician Certification Board (PTCB). All of its customer service representatives are licensed through the Kentucky Board of Pharmacy.
Today, HealthWarehouse.com announced that its net sales for 2016 grew 48 percent to $10.4 million versus $7.0 million the year prior. The Company credited its 2016 sales performance to growth in core consumer prescription and over-the-counter (OTC) product sales. Total orders grew 78 percent from 150,322 orders in 2015 to 268,334 orders in 2016.
HealthWarehouse.com reported a net loss of $96,944 for the quarter ended December 31, 2016. This included $66,348 of nonrecurring annual meeting proxy and solicitation costs and severance expense for departing executives. The net loss was $86,665 less than the $183,609 net loss during Q4 of 2015. The net loss for the year ended December 31, 2016 was $1,408,203 versus a $626,682 net loss for the year ended December 31, 2015. The 2016 results include $854,651 of nonrecurring expenses.
HealthWarehouse.com, Inc. (HEWA), closed Monday's trading session at $0.23, up 4.55%, on 181,676 volume with 36 trades. The average volume for the last 60 days is 34,749 and the stock's 52-week low/high is $0.21/$0.85.
Saker Aviation Services, Inc. (SKAS)
Zacks, PennyStocks24, AwesomeStocks, Chatter Box Stocks, SquawkBoxStocks, and TerrificPennyStocks reported earlier on Saker Aviation Services, Inc. (SKAS), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Saker Aviation Services, Inc. serves as the operator of a heliport, a fixed base operation (FBO), and as a consultant for a seaplane base that it does not own. The Company specializes in ground-based services to the general aviation market. Saker' devotion is to providing concierge-level aviation services for individuals and corporate clients with an emphasis on safety. Saker Aviation Services is based in New York, New York.
Saker Aviation Services has locations in the Northeast and Midwest. Pertaining to FBOs, these provide ground-based services. This includes fueling and aircraft storage for general aviation, commercial and military aircraft, and other miscellaneous services. The Company’s set of full service FBOs can provide a fast-turn or complete concierge amenities and reservations.
Saker Aviation Services is an Avfuel branded dealer. Avfuel Corp. is the nation's leading independent supplier of aviation fuels and services. In addition, Saker has an experienced maintenance, concierge, as well as charter staff. The Company helps its clients with all of their aircraft management needs.
Saker JRB is located at the base of Wall Street, above the Battery on Pier 6, on the East River north of the Staten Island Ferry and south of the South Street Seaport. This Downtown Manhattan Heliport is one of the most advanced heliports in the industry. Its emphasis is user comfort and convenience. Saker JRB has ramp parking that accommodates helicopters up to 50,000 pounds. Its terminal provides a VIP lounge, flight operations, and general administrative office space.
The heliport provides services for the world’s most prestigious multinational corporations, trading organizations, and legal firms in Manhattan. This is in addition to it offering daily sightseeing tours.
A Nevada corporation, Saker Aviation Services established on January 17, 2003. Saker became a public company because of a reverse merger transaction on August 20, 2004. On September 2, 2009, the Company changed its name to Saker Aviation Services, Inc. Its common stock is publicly traded on the OTC Markets Group’s OTCQB.
Saker has recently acquired Aircraft Services, Inc. in Garden City, Kansas. Its wholly-owned subsidiary, FBO Air Garden City, Inc. (GCK), entered into a Stock Purchase Agreement, dated October 3, 2016, by and between GCK and Gary and Kim Keller, to buy all of the capital stock of Aircraft Services, Inc., which is an aircraft maintenance services enterprise.
Saker Aviation Services, Inc. (SKAS), closed Monday's trading session at $0.227, up 26.11%, on 105,719 volume with 33 trades. The average volume for the last 60 days is 88,427 and the stock's 52-week low/high is $0.04/$0.3997.
NanoFlex Power Corp. (OPVS)
We are reporting on NanoFlex Power Corp. (OPVS) today, here at the QualityStocks Daily Newsletter.
NanoFlex Power Corp. engages in the research, development, and commercialization of advanced configuration solar technologies. These technologies enable inventive thin-film solar cell implementations. NanoFlex believes these will be industry-leading efficiencies, light weight, flexible, and low total system cost. NanoFlex Power is based in Scottsdale, Arizona and the Company lists on the OTCQB.
The Company’s sponsored research programs at USC, Michigan, and Princeton University have resulted in a broad portfolio of issued and pending patents, worldwide, covering flexible, thin-film photovoltaic technologies. Its sponsored research programs with the University of Southern California and the University of Michigan have resulted in an IP portfolio consisting of greater than 700 issued or pending patents internationally.
Its research programs have produced two solar thin film technology platforms. These are: Gallium Arsenide (GaAs) thin film technology for high power applications and organic photovoltaic (OPV) technology for applications necessitating high quality aesthetics, such as semi-transparency and tinting and ultra-flexible form factors.
The targeting of these technologies is at specific wide-ranging applications. These include mobile and off-grid power generation; building applied photovoltaics (BAPV); and building integrated photovoltaics (BIPV). Moreover, these include space vehicles and unmanned aerial vehicles (UAVs); semi-transparent photovoltaic windows or glazing; and ultra-thin solar films or paints for automobiles or other consumer applications.
NanoFlex Power’s sponsored research agreements provide the Company with the exclusive global license and right to sublicense any and all intellectual property (IP) resulting from the related research and development (R&D) efforts at the above-mentioned universities.
NanoFlex Power is centering on two parallel technology development efforts. Its inorganic GaAs architectures, manufacturing processes, and technologies aim to provide solar cell manufacturers with the capability of producing thin film GaAs solar cells with ultra-high efficiencies at a cost less than $1 per watt for applications including mobile and field generation, BAPV, BIPV and aerospace that are not well-served by crystalline silicon solar technologies.
Also, the Company’s portfolio of OPV thin film solar technologies aim to provide low-cost and highly flexible solar energy solutions for new applications. These include BIPV (tinted or semi-transparent solar films for glass surfaces) and ultra-thin films for coatings on automobiles, and more.
Last month, NanoFlex Power announced it entered into a license agreement with SolAero Technologies Corporation. For the last two years, NanoFlex and SolAero have partnered to validate NanoFlex's patented, non-destructive epitaxial lift-off (ND-ELO) process and related technologies in SolAero's ultra-high efficiency solar cells. SolAero is a worldwide leader in high performance photovoltaics for space and terrestrial applications.
NanoFlex Power has the exclusive global rights to license, sublicense, and bring its own products to market utilizing ND-ELO technology. ND-ELO technology has the potential to decrease compound semiconductor production costs by over 40 percent through enabling reuse of the expensive wafer substrate. This pioneering process technology was invented at the University of Michigan by Professor Steven Forrest's research team. NanoFlex Power has further developed it.
NanoFlex Power Corp. (OPVS), closed Monday's trading session at $0.765, up 17.69%, on 5,550 volume with 4 trades. The average volume for the last 60 days is 13,789 and the stock's 52-week low/high is $0.201/$2.10.
2050 Motors, Inc. (ETFM)
BestDamnPennyStocks, DSR News, Fortune Stock Alerts, Penny Stock Hub, PennyPickAlerts, The Next Big Trade, SmallCap Network, and Market Authority reported earlier on 2050 Motors, Inc. (ETFM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
2050 Motors, Inc. formed to develop and produce the next generation of clean, lightweight, efficient vehicles and its associated technologies. Some of the technologies include alternative renewable fuels, hybrid electric vehicles, advanced graphene lithium batteries, and carbon fiber low cost vehicles. Incorporated in 2012, 2050 Motors has its headquarters in North Las Vegas, Nevada. The Company lists on the OTC Markets Group’s OTCQB.
2050 Motors has been successful in establishing long term relationships and exclusive contracts for a variety of game changing technologies. The Company entered into an agreement with Jiangsu Aoxin New Energy Automobile Co., Ltd., in Jiangsu, China. This agreement is for the distribution in the United States of a new electric automobile, called the e-Go EV (electric vehicle).
The e-Go EV is a leading-edge new concept in the developing world of electric vehicles. It will be the only production line electric car with a carbon fiber body and parts manufactured by a new process employing robotic machines that significantly decreases the fabrication time and cost of carbon fiber components.
The e-Go EV will seat four passengers, have a long battery life, and high energy efficiency rating up to 150+ MPG-E energy equivalent in urban driving owing to the light weight of the vehicle. The five passenger carbon fiber luxury sedan Ibis EV is the e-Go's big brother. It will also be showcased along with the e-Go EV for future sales in the U.S.
Fundamentally, 2050 Motors is involved in all aspects of automobile technology. This includes advanced batteries, high efficiency and alternate fuel engines, hybrid vehicles, production of graphene, and composite materials.
2050 Motors is awaiting the arrival of the first assembly line shipment of the new all carbon fiber e-Go automobiles to the U.S. to schedule crash testing per US DOT standards. This will happen as soon as the new Aoxin e-Go manufacturing plant receives its permit to produce vehicles.
The e-Go has already passed preliminary crash testing at the CATARC Institute in China according to Chinese, Japanese and European standards. 2050 Motors said that it and Aoxin will continue their work to achieve the ultimate goal of producing and distributing some of the most advanced carbon fiber electric automobiles globally.
2050 Motors, Inc. (ETFM), closed Monday's trading session at $0.063, down 23.45%, on 4,310 volume with 2 trades. The average volume for the last 60 days is 23,712 and the stock's 52-week low/high is $0.04/$0.34.
CURE Pharmaceutical Holding Corp. (CURR)
We are reporting on CURE Pharmaceutical Holding Corp. (CURR) today, here at the QualityStocks Daily Newsletter.
CURE Pharmaceutical Holding Corp. is a developer and manufacturer of advanced oral thin film (CureFilm™) for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter (OTC) applications. The Company is a fully integrated, progressive drug delivery enterprise. CURE has an industry leading full service cGMP manufacturing facility. CURE Pharmaceutical Holding has its corporate office in Oxnard, California.
The Company provides the most advanced development and manufacturing of CureFilm™ pharmaceutical and veterinarian products in a patented and proprietary delivery system. CURE has also an assortment of products in leading-edge delivery platforms, including sublingual and transdermal applications.
CURE Pharmaceutical takes products through the clinical process to commercialization. The Company serves the pharmaceutical and biotech; veterinarian; nutraceutical and medical food; and cannabinoid drug molecules market vertical sectors.
CureFilm™ drug delivery is a next generation market alternative to traditional tablets, capsules, and liquids when delivering prescription, and OTC medications. The design of CureFilm™ is for oral administration employing the sublingual or buccal area of the mouth. CureFilm™ has undergone development to improve upon pharma kinetic profile and the overall therapeutic index of API (Active Pharmaceutical Ingredient).
The Company is investing heavily in the development of new drug delivery technology advancements. Advances CURE has made include enhanced encapsulation and nano-encapsulation technologies, composition formulations, stability systems, taste masking systems, production methodologies, and primary packaging advancements.
CURE Pharmaceutical continues to seek and welcome strategic partners in the pharmaceutical partners – human and veterinary; emerging pharmaceutical markets – human and veterinary; non-government organizations; medical institutions; and cosmetic and skin-care areas.
The Company can manufacture and distribute technically complex formulations, packaging and product lines of medicines, which meet exacting standards for quality and effectiveness. CURE’s process development and manufacturing expertise is enabling it to deliver multiple delivery platforms of increasing complexity.
In essence, CURE’s technology enables differentiation within large therapeutic categories. It potentially improves patient compliance via its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing efficacy, therefore broadening the therapeutic index.
CURE Pharmaceutical Holding Corp. (CURR), closed Monday's trading session at $6.30, up 14.75%, on 84,278 volume with 217 trades. The average volume for the last 60 days is 9,018 and the stock's 52-week low/high is $2.0499/$5.49.
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.89, up 15.14%, on 6,274 volume with 12 trades. The stock’s average daily volume over the past 60 days is 6,771, and its 52-week low/high is $1.33/$4.35.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Monaker Group to Present at the 29th Annual ROTH Conference, March 15, 2017
Monaker Group Appoints Robert Post to Board of Directors
Monaker Group Appoints Simon Orange to Board of Directors Appointment Advances Monaker's Plans for NASDAQ Listing
InMed Pharmaceuticals, Inc. (IMLFF)
The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2979, up 11.20%, on 847,886 volume with 413 trades. The stock’s average daily volume over the past 60 days is 819,850, and its 52-week low/high is $0.05/$0.4261.
InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”
After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.
Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.
Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer
InMed Pharmaceuticals, Inc. Company Blog
InMed Pharmaceuticals, Inc. News:
InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media
InMed Receives over $1,350,000 From Warrant Exercise
India Globalization Capital, Inc. (IGC)
The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.312, up 5.87%, on 98,651 volume with 243 trades. The stock’s average daily volume over the past 60 days is 169,115, and its 52-week low/high is $0.19/$0.83.
India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer
India Globalization Capital, Inc. Company Blog
India Globalization Capital, Inc. News:
IGC Announces Third Quarter Financial Results
India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant to its CFO
IGC Update on Iron Ore Subsidiary
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0007, even for the day, on 12,733,764 volume with 34 trades. The stock’s average daily volume over the past 60 days is 14,300,589 and its 52-week low/high is $0.0006/$0.028.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Dominovas Energy Dispatches Watkins to Meet With Gas Supplier
ProBility Media Corp. (PBYA)
The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.726, even with yesterday's close. The stock’s average daily volume over the past 60 days is 915, and its 52-week low/high is $0.2254/$1.50.
ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.
Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.
Companies currently under the ProBility Media conglomerate include:
- Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
- Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
- 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
- National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.
ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.
The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer
ProBility Media Corp. Company Blog
ProBility Media Corp. News:
ProBility Media Corp. and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
ProBility Media Corp. Announces Philanthropic Initiative
Panther Biotechnology Inc. Announces Name Change to ProBility Media Corp.
Today's Top 3
Profitable Trader Authority
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- ChineseInvestors.com, Inc. (CIIX) SeeThruEquity Issues Update on ChineseInvestors.com, Increasing Price Target to $3.75
- Dominovas Energy Corp. (DNRG) Enters Formal Negotiations to Open in India and Indonesia
- eXp World Holdings, Inc. (EXPI) to Present at Annual ROTH Conference
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) IGC Announces Third Quarter Financial Results
- InMed Pharmaceuticals Inc. (IMLFF) InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Releases Exclusive Audio Interview with ORHub
- ProBility Media Corp. (PBYA) and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
- Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
- Singlepoint, Inc. (SING) Greg Lambrecht, CEO of SinglePoint, Discusses Recent SING News and Industry Trends in A New Audio Interview withSmallCapVoice.com
- Stealth Technologies, Inc. (STTH) Announces 5 New Products